Results 201 to 210 of about 18,395 (294)

Efficacy and safety of modified-dose obinutuzumab in the treatment of refractory membranous nephropathy. [PDF]

Front Immunol
Zhou J, Ai S, Zhang X, Wang X, Chen G, Wang Y.   +5 more
europepmc   +1 more source

Obinutuzumab versus rituximab in refractory membranous nephropathy: a single-center retrospective cohort study. [PDF]

BMC Nephrol
Lei W, Lai HP, Lv Y, Jin L, Xin J.
europepmc   +1 more source

NAT10‐mediated N4‐acetylcytidine modification drives RNA splicing of PML to alleviate adipose‐derived stem cell senescence and promote diabetic wound healing

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
N‐acetyltransferase 10 (NAT10) catalyses N4‐acetylcytidine (ac4C) modification of PML pre‐mRNA, shifting splicing from the senescence‐promoting PML‐FL to the senescence‐inhibiting PML‐S isoform via SRSF1. This rejuvenates adipose‐derived stem cells (ADSCs) by reducing senescence markers and senescence‐associated secretory phenotype (SASP), thereby ...
Wuhan Wei, Chanyuan Jiang, Dong Zhu, Xuefeng Han, Xuan Ma, Xinyu Jia, Jiaqi Ling, Rui Zhang, Facheng Li, Ningbei Yin   +9 more
wiley   +1 more source

Multiplexed Detection of Membranous Nephropathy Antigens by Multi-Reaction Monitoring Mass Spectrometry. [PDF]

Kidney Int Rep
Storey AJ, Caza TN, Hassen SI, Stephens OW, Vanhouten L, Edmondson R, Kenan D, Larsen CP.   +7 more
europepmc   +1 more source

Harnessing Fatty Acid By‐Products for Diabetes Management: Insights From Nutritional and Biological Research

eFood, Volume 7, Issue 3, June 2026.
Bioactive fatty acids from agro‐industrial byproducts are highlighted as a promising avenue for managing diabetes in this review, which aims to develop targeted interventions for optimal utilization and therapeutic benefits. ABSTRACT Diabetes mellitus (DM), influenced by multifaceted factors, creates a complex imbalance within the body. Nutrition plays
Youssef Elouafy, Abdelaali Balahbib, Meriem El Fessikh, Saïd Gharby, Nasreddine El Omari, Waleed Al Abdulmonem, Gokhan Zengin, Abdelhakim Bouyahya   +7 more
wiley   +1 more source

Reconsideration of Response Assessment in Obinutuzumab-Treated Membranous Nephropathy. [PDF]

Kidney Int Rep
Atay İ, Eröz E, Heybeli C.
europepmc   +1 more source

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

Case Report: A case of rituximab for membranous nephropathy secondary to primary Sjogren's syndrome and literature review. [PDF]

Front Immunol
Fu X, Gao F, Zang L, Mao N.
europepmc   +1 more source

Functional Bread From Bambara Groundnut and Orange Peel Attenuates Hyperglycemia and Oxidative Stress in a High‐Fat Diet/Streptozotocin‐Induced Type 2 Diabetes Rat Model

Food Chemistry International, Volume 2, Issue 2, Page 211-221, June 2026.
This study evaluated Bambara groundnut–wheat composite bread fortified with orange peel in diabetic rats. Diets significantly lowered blood glucose, inhibited α‐glucosidase and α‐amylase, and boosted antioxidant enzymes compared to controls. Results emphasize BG‐based functional foods' potential to help manage type 2 diabetes through regulation of ...
S. O. Oguntuase, O. W. Fasakin, I. S. Oyeleye, G. Oboh   +3 more
wiley   +1 more source

Rituximab for the treatment of membranous nephropathy in a patient with ankylosing spondylitis: a case report. [PDF]

Front Med (Lausanne)
Zhong R, Su L, Li H, Zhu H, Xiao Z.
europepmc   +1 more source